Related references
Note: Only part of the references are listed.Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates
Jerry Powell et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A
Thierry Calvez et al.
BLOOD (2014)
Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011
Peter W. Collins et al.
BLOOD (2014)
The first recombinant FVIII produced in human cells - an update on its clinical development programme
L. A. Valentino et al.
HAEMOPHILIA (2014)
Pharmacokinetic analysis of anti-hemophilic factor in the obese patient
A. Graham et al.
HAEMOPHILIA (2014)
Compliance, concordance and adherence: what are we talking about?
K. Khair
HAEMOPHILIA (2014)
Novel products for haemostasis - current status
J. Oldenburg et al.
HAEMOPHILIA (2014)
Similar bleeding phenotype in young children with haemophilia A or B: a cohort study
N. Clausen et al.
HAEMOPHILIA (2014)
Kreuth III: European consensus proposals for treatment of haemophilia with coagulation factor concentrates
P. Giangrande et al.
HAEMOPHILIA (2014)
Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
T. E. Coyle et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Definitions in hemophilia: communication from the SSC of the ISTH
V. S. Blanchette et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Inhibitors and prophylaxis in paediatric haemophilia patients: Focus on the German experience
Karin Kurnik et al.
THROMBOSIS RESEARCH (2014)
Intermediate- dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s
Kathelijn Fischer et al.
BLOOD (2013)
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study
Samantha C. Gouw et al.
BLOOD (2013)
Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice
Giovanni Di Minno et al.
HAEMATOLOGICA (2013)
Population pharmacokinetics of recombinant factor IX: implications for dose tailoring
S. Bjorkman
HAEMOPHILIA (2013)
Is haemophilia B less severe than haemophilia A?
P. M. Mannucci et al.
HAEMOPHILIA (2013)
Consequences of switching from prophylactic treatment to on-demand treatment in late teens and early adults with severe haemophilia A: the TEEN/TWEN study
M. J. Manco-Johnson et al.
HAEMOPHILIA (2013)
Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study
P. Hilliard et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)
M. J. Manco-Johnson et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B
Jerry S. Powell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Factor VIII Products and Inhibitor Development in Severe Hemophilia A
Samantha C. Gouw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Emerging Issues on Comprehensive Hemophilia Care: Preventing, Identifying, and Monitoring Age-Related Comorbidities
Antonio Coppola et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2013)
Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight
Sven Bjorkman et al.
BLOOD (2012)
Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life
Mohammed Khawaji et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients - long-term follow-up and continuing experience
G. Auerswald et al.
HAEMOPHILIA (2012)
Feasibility of short message service to document bleeding episodes in children with haemophilia
C. R. Broderick et al.
HAEMOPHILIA (2012)
Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy
K. Lindvall et al.
HAEMOPHILIA (2012)
WFH: Closing the global gap - achieving optimal care
Mark W. Skinner
HAEMOPHILIA (2012)
Association Between Physical Activity and Risk of Bleeding in Children With Hemophilia
Carolyn R. Broderick et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management
L. A. Valentino et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada
J. Kraft et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B
Claude Negrier et al.
BLOOD (2011)
Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States
Char Witmer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Treatment related factors and inhibitor development in children with severe haemophilia A
P. S. Maclean et al.
HAEMOPHILIA (2011)
Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia
P. W. Collins et al.
HAEMOPHILIA (2011)
Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
Baisong Mei et al.
BLOOD (2010)
A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A
Michael Richards et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review
A. Iorio et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens
P. W. Collins et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders
Giuseppe Tagariello et al.
BLOOD (2009)
Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years
Sven Bjorkman et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
P. W. Collins et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Intracranial haemorrhage in haemophilia A and B
Rolf C. R. Ljung
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers)
P. M. Mannucci et al.
HAEMOPHILIA (2007)
Intracranial bleeding in haemophilia beyond the neonatal period - the role of CT imaging in suspected intracranial bleeding
C. Traivaree et al.
HAEMOPHILIA (2007)
Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data
M. Richards et al.
HAEMOPHILIA (2007)
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Marilyn J. Manco-Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Transfusion Medicine 3 - Coagulation factor concentrates: past,, present, and future
Nigel S. Key et al.
LANCET (2007)
Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV
Sarah C. Darby et al.
BLOOD (2007)
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study
Samantha C. Gouw et al.
BLOOD (2007)
The risk associated with indwelling catheters in children with haemophilia
Rolf Ljung
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study
BM Feldman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Compliance with treatment and understanding of own disease in patients with severe and moderate haemophilia
K Lindvall et al.
HAEMOPHILIA (2006)
Intracranial haemorrhages in French haemophilia patients (1991-2001): clinical presentation, management and prognosis factors for death
N Stieltjes et al.
HAEMOPHILIA (2005)
Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study
E Santagostino et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands
K van Dijk et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Prophylactic treatment effects on inhibitor risk: experience in one centre
M Morado et al.
HAEMOPHILIA (2005)
MRI scores of ankle joints in children with haemophilia - comparison with clinical data
B Lundin et al.
HAEMOPHILIA (2005)
Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome
K Fischer et al.
HAEMOPHILIA (2001)
Share Paper
